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Kaposi’s sarcoma-associated herpesvirus (KSHV) has been linked to the development of Kaposi’s sarcoma, primary effusion
lymphoma, and multicentric Castleman’s disease (MCD). We have characterized the role of KSHV-encoded viral FLICE inhibi-
tory protein (vFLIP) K13 in the modulation of anti-IgM-induced growth arrest and apoptosis in B cells. We demonstrate that
K13 protects WEHI 231, an immature B-cell line, against anti-IgM-induced growth arrest and apoptosis. The protective effect of
K13 was associated with the activation of the NF-B pathway and was deficient in a mutant K13 with three alanine substitutions
at positions 58 to 60 (K13-58AAA) and a structural homolog, vFLIP E8, both of which lack NF-B activity. K13 upregulated the
expression of NF-B subunit RelB and blocked the anti-IgM-induced decline in c-Myc and rise in p27Kip1 that have been associ-
ated with growth arrest and apoptosis. K13 also upregulated the expression of Mcl-1, an antiapoptotic member of the Bcl2 fam-
ily. Finally, K13 protected the mature B-cell line Ramos against anti-IgM-induced apoptosis through NF-B activation. Inhibi-
tion of anti-IgM-induced apoptosis by K13 may contribute to the development of KSHV-associated lymphoproliferative
disorders.
B-cell receptor (BCR)-induced apoptosis of self-reactive imma-ture B cells is one of the defining mechanisms underlying B-
lymphocyte development and immune tolerance (1). Immature B
cells in the bone marrow, upon successful rearrangement of their
light chains, begin to express the BCR (IgM)on their surface (1, 2).
Engagement of the BCR with self-antigens results in cells arrest-
ing, undergoing receptor editing and clonal deletion (2). Several
rounds of this negative selection occur before the B cells leave the
bone marrow to migrate to the spleen in an effort to prevent au-
toreactivity. Functional studies have highlighted a role for the
NF-B pathway in the survival of immature B cells during nega-
tive selection and an absolute critical role for this pathway during
B-cell survival and development in the spleen (3).
Kaposi’s sarcoma-associated herpesvirus (KSHV), also known
as human herpesvirus 8 (HHV8), is a gammaherpesvirus 2 that
was originally identified in Kaposi sarcoma (KS) lesions from
HIV-1-infected individuals (4). Subsequently, it was shown that
KSHV is also associated with two lymphoproliferative disorders,
primary effusion lymphoma (PEL) and a plasmablastic variant of
multicentric Castleman’s disease (MCD) (5, 6). MCD is charac-
terized by the presence of large abnormal polyclonal plasmablasts
in the mantle zones of B-cell follicles that express high levels of
cytoplasmic and surface immunoglobulin that is IgM() re-
stricted (7–9).
K13 protein is one of the fewKSHVproteins that are expressed
in latently infected cells. K13 contains two death effector domains
and was initially classified as a viral FLICE inhibitory protein
(vFLIP) based on its homology to the prodomain of caspase-8/
FLICE (10). However, subsequent studies by this laboratory and
others have shown that K13 does not act as an inhibitor of
caspase-8 but, rather, acts as a potent activator of both the classic
and the alternative nuclear factor-kappa B (NF-B) pathways
(11–14). K13 successfully utilizes theNF-Bpathway to initiate an
extensive range of cellular processes that promote survival, prolif-
eration, differentiation, cytokine secretion, and oncogenic trans-
formation and protect cells against growth factor withdrawal-in-
duced apoptosis (15–20).
Based on the ability of K13 to strongly activate theNF-Bpath-
way, we postulated that it may protect autoreactive B cells from
BCR-induced growth arrest and apoptosis. In this report, we ex-
amined this hypothesis by employing two different cell line mod-
els of BCR-induced apoptosis. First, we used the phenotypically
immature IgM-positive cell line WEHI 231, which represents a
population that is characteristically similar to immature B lym-
phocytes both on the basis of surfacemarkers and biological prop-
erties (21). Second, we used the phenotypically mature Burkitt
lymphoma human B-cell line Ramos to examine whether the pro-
tective effective of K13 is sustained through B-cellmaturation.We
show that expression of K13 in both WEHI 231 and Ramos cell
lines confers protection against anti-IgM-induced apoptosis
through activation of the NF-B pathway.
MATERIALS AND METHODS
Cell culture, plasmids, and reagents. WEHI 231 cells were grown inDul-
becco’s modified Eagle’s medium (Invitrogen Life Technologies) supple-
mented with 10% (vol/vol) fetal bovine serum and 50 M 2--mercap-
toethanol. Ramos cells were grown in RPMI 1640medium supplemented
with 10% (vol/vol) fetal bovine serum (both from Life Technologies).
Retrovirus constructs containing C-terminal FLAG epitope-tagged wild-
type and mutant vFLIP K13 and E8 have been described previously (13,
20). K13-ERTAM cells stably expressing an NF-B-driven luciferase re-
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porter construct (K13-ERTAM-NF-B-Luc) were generated in WEHI 231
cells as previously described (22). The wild-type and mutant relB lucifer-
ase reporter constructs were kind gifts of X. Dong (Mayo Clinic College of
Medicine, Rochester, MN) (23). The MSCV-puro-WT-Mcl-1 (where
MSCV ismurine stem cell virus andWT is wild type) construct was a kind
gift from J. Opferman (Department of Biochemistry, St Jude Children’s
Hospital,Memphis, TN). All infectionswere carried out in the presence of
Polybrene (8 g/ml; Sigma, St. Louis, MO). Goat anti-mouse IgM, 
chain specific, and goat anti-human IgM were purchased from Jackson
ImmunoResearch Laboratories, Inc. (West Grove, PA); 4-hydroxytamox-
ifen (4OHT) and As2O3 were from Sigma (St. Louis, MO). JQ1 was gen-
erously provided by James Bradner (Dana-Farber Cancer Institute).
Cell viability and cell cycle assays. Cells from exponentially growing
cultures were plated in an untreated, flat-bottom 96-well plate at a density
of 1 104 cells/well in the presence and absence of anti-IgM. Cell viability
was measured after 48 h using MTS reagent [3-4,5-dimethylthiazol-2yl)-
5-(3-carboxy-methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt]
following themanufacturer’s instructions (Promega,Madison,WI). K13-
ERTAM cells were cultured with or without 4OHT (20 nM) and treated
with anti-IgM for 24 h and 48 h. DNA content analysis was performed as
previously described (24). Apoptotic analysis was conducted using an
Annexin V-PE Apoptosis Detection Kit I according to the manufacturer’s
instructions (BD Biosciences San Jose, CA) and also analyzed on a BD
Biosciences LSR II instrument.
Luciferase reporter assay. 293T cells were transfected in a 24-well
plate with various test plasmids along with wild-type and mutant relB
luciferase reporter constructs (75 ng/well) and a pRSV/LacZ (-galacto-
sidase) reporter construct (75 ng/well) as described previously (11). Cells
were lysed 24 to 36 h later, and extracts were used for the measurement of
firefly luciferase and-galactosidase activities, respectively. Luciferase ac-
tivity was normalized relative to the -galactosidase activity to control for
the difference in the transfection efficiencies.
Western blot analysis. Western blot analysis was performed as previ-
ously described (25). Primary antibodies used in Western blotting exper-
iments were FLAG-horseradish peroxidase (HRP; 1:25,000) (A8592;
Sigma), A20 (1:1,000) (5630s; Cell Signaling), phospho-IB (1:1,000;
Ser32) (2859s; Cell Signaling), Mcl-1 (1:1,000) (sc-19; Santa Cruz), RelB
(1:1,000) (sc-226; Santa Cruz), IB- (1:1,000) (sc-864; Santa Cruz),
p27(1:1,000) (sc-1641; Santa Cruz), c-Myc (1:10,000) (1472-1; Epitom-
ics), and tubulin (1:10,000) (T9026; Sigma). A mouse monoclonal anti-
body against the full-length K13 protein (8F6) was generated in our lab-
oratory. For Western blots developed by Odyssey Infrared Imaging
System CLx (Li-Cor Biosciences), the secondary antibodies, IRDye
800CW conjugates of goat anti-rabbit IgG (Li-Cor) and goat anti-mouse
IgG (Li-Cor), were used at a 1:10,000 dilution for detection of antibody
targets in the 800-nmchannel. The blotswere scanned and analyzed using an
Odyssey Infrared scanner using Odyssey imaging software, version 2.0.
Assays for nuclear NF-B DNA binding activity and luciferase ac-
tivity. The DNA binding activity of the p65 subunit was measured in
triplicate in the nuclear extracts of WEHI 231 and Ramos cells using an
enzyme-linked immunosorbent assay (ELISA)-based assay as previously
described (26). The NF-B luciferase assay was performed essentially as
previously described (27).
RNA interference. Short interfering RNA (siRNA) oligonucleotides
againstmouse RelB,mouse c-Myc, andmouseMcl-1 and a control siRNA
were purchased from Santa Cruz Biotechnology.WEHI 231 cells express-
ing K13 or K13-ERTAM (WEHI 231-K13 or WEHI 231-K13-ERTAM, re-
spectively) were transfected with these siRNA oligonucleotides using a
Neon transfection system (Invitrogen) as per the manufacturer’s recom-
mendations.
Real-time PCR. Total RNA was isolated using an RNeasy Mini Kit
(Qiagen), and cDNA was synthesized using the reverse transcriptase en-
zyme Superscript II (Invitrogen). Real-time quantitative reverse tran-
scription-PCR (qRT-PCR) was performed with SYBR green, using
c-Myc-specific PCR primers. Samples were run in triplicate, and PCRwas
performed by an ABI Step One Plus thermocycler (Applied Biosystems).
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as
housekeeping gene, and qRT-PCRdata (threshold cycle [CT] values) were
analyzed using the 2 Cmethod as described earlier (26). The qRT-PCR
data were presented as fold change in target gene expression	 standard
deviation.
Statistical analysis. Statistical analyses were performed using un-
paired t tests. Values are expressed as means	 standard deviations (SD),
with all experiments repeated a minimum of three times with triplicate
samples. A P value of0.05 was considered statistically significant.
RESULTS
K13 protects WEHI 231 cells from anti-IgM-induced growth in-
hibition. Treatment of WEHI 231 cells with anti-IgM leads to
growth inhibition and ultimately cell death (21). We generated
polyclonal populations of WEHI 231 cells expressing FLAG-
tagged K13 and an empty vector using retroviral gene transfer and
confirmed expression of K13 by immunoblotting with an anti-
body against the FLAGepitope tag (Fig. 1A). Furthermore, immu-
noblotting with a monoclonal antibody (8F6) against K13 con-
firmed that the level of ectopically expressed K13 in WEHI 231
cells was comparable to the physiological level of K13 found in the
PEL cell line BC1 (Fig. 1B).We next examined the ability of K13 to
protect against anti-IgM-induced growth inhibition by growing
WEHI 231 cells expressing an empty vector (WEHI 231-vector)
and WEHI 231-K13 with increasing concentrations of anti-IgM.
WEHI 231-vector cells showed a dramatic and dose-dependent
reduction in cell number upon treatment with anti-IgM (Fig. 1C).
In contrast, the expression of K13 conferred significant protection
FIG 1 K13 protectsWEHI 231 cells from anti-IgM induced growth inhibition.
(A) Expression of FLAG-K13 inWEHI 231 cells. K13was immunoprecipitated
(IP) by FLAG antibody beads fromWEHI 231 cells stably expressing an empty
vector or FLAG-tagged K13 followed by immunoblot (IB) analysis with a
FLAG antibody. (B) Level of ectopic K13 inWEHI 231 cells compared with its
physiological level in the KSHV-infected PEL cell line BC1. Immunoblotting
was performed using 8F6 monoclonal antibody against K13; a nonspecific
band (NS) serves as a loading control. (C)WEHI 231 cells expressing an empty
vector or K13 were grown in triplicate in a 96-well plate with the indicated
concentrations of anti-IgM for 48 h. Cell viability wasmeasured using theMTS
assay (values aremeans	 SD; n
 3). (D) Expression of FLAG-K13-ERTAM in
WEHI 231 cells, asmeasured byWestern blotting. (E)WEHI 231 cells express-
ing K13-ERTAM grown in the presence and absence of 4OHT (20 nM) were
treated in triplicate with the indicated concentrations of anti-IgM for 48 h. Cell
viability was measured using the MTS assay (values are means	 SD; n
 3).
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against the growth inhibition caused by the anti-IgM treatment
(Fig. 1C).
We also generated stable populations of WEHI 231 cells ex-
pressing a K13-ERTAM fusion construct (Fig. 1D). The K13-
ERTAM fusion protein is expressed constitutively in WEHI 231
cells but becomes active only on the addition of 4-hydroxytamox-
ifen (4OHT), thus allowing posttranslational control of K13 ac-
tivity (17). We grew WEHI 231-K13-ERTAM cells in the presence
and absence of 4OHT (20 nM) for 16 h and then treated themwith
increasing concentrations of anti-IgM. While the untreated
WEHI 231-K13-ERTAM cells showed dramatic growth inhibition
upon anti-IgM treatment, 4OHT-treated cells were relatively re-
sistant (Fig. 1E). Taken collectively, the above results demonstrate
that K13 confers protection against anti-IgM-induced growth in-
hibition in WEHI 231 cells.
K13 inhibits anti-IgM-induced cell cycle arrest and anti-
IgM-induced apoptosis in WEHI 231 cells. To study the mecha-
nism by which K13 protects against anti-IgM-induced growth ar-
rest, we carried out cell cycle analysis.WEHI 231-K13-ERTAM cells
were grown in the presence and absence of 20 nM 4OHT and
subsequently treated with anti-IgM for 48 h. The cell cycle distri-
bution profiles of propidium iodide-stained cells were measured
by flow cytometry (Fig. 2A). Treatment ofWEHI 231-K13-ERTAM
cells with anti-IgM for 48 h resulted in an increase in cells inG0/G1
phase from 30% to 94% and a reduction of cells in S phase from
56% to 3%, reflecting cell cycle arrest in the G0/G1 phase. In con-
trast, anti-IgM treatment of K13-ERTAM cells that had been pre-
treated with 4OHT resulted in an increase in cells in G0/G1 phase
from 27% to 50% and a reduction of cells in S phase from 57% to
37%. Thus, K13 was able to significantly block the G0/G1 cell cycle
arrest induced by anti-IgM treatment.
In addition to inducing cell cycle arrest, B-cell receptor stimu-
lation of WEHI 231 cells is known to result in apoptosis. To de-
termine if K13 also protects against anti-IgM-induced apoptosis,
cells were analyzed using flow cytometry following staining with
annexin V, a marker of apoptosis. Treatment of WEHI 231-K13-
ERTAM cells with anti-IgM resulted in an almost doubling of an-
nexin V-positive cells, which was significantly blocked by pre-
treatment with 4OHT (Fig. 2B). The protective effect of K13
against anti-IgM-induced apoptosis was confirmed by staining
with Sytox Green, a membrane-impermeable nuclear dye that
stains the nuclei of only dead and dying cells that have lost cell
membrane integrity. K13-ERTAM cells were treatedwith 4OHT for
16 h or left untreated and were subsequently grown for 48 h in the
presence or absence of 1 g/ml anti-IgM. Apoptotic cells were
evaluated under phase-contrast and fluorescence microscopy.
Anti-IgM treatment of K13-ERTAM cells resulted in the appear-
ance of cells with brightly stained, condensed and fragmented nu-
clei, suggestive of loss of membrane integrity and induction of
apoptosis (Fig. 2C). The Sytox Green-positive cells weremarkedly
reduced among anti-IgM-treated K13-ERTAM cells that had been
grown in the presence of 4OHT (Fig. 2C).
Protective effect of K13 against anti-IgM-induced apoptosis
is associated with upregulation of NF-B activity. The NF-B
pathway has been reported to be constitutively active in theWEHI
231 cells, and anti-IgM-induced apoptosis of these cells has been
shown to be associated with a drop in NF-B activity (28, 29).
Since K13 is known to activate the NF-B pathway, we next ex-
amined whether it protects against anti-IgM-induced apoptosis
by blocking the drop in NF-B activity observed following anti-
IgM treatment. For this purpose, WEHI 231-vector and -K13-
ERTAM cells were grown in the presence and absence of 4OHT and
then stimulated with anti-IgM for 24 h. The status of the NF-B
pathway was examined using a nuclear p65/RelA DNA binding
assay. Consistent with published reports (28, 29), nuclear extracts
fromWEHI 231-vector cells that had been grown in the absence or
presence of 4OHT showed modest basal p65/RelA DNA binding
activity, whichwas significantly reduced following anti-IgM treat-
ment (Fig. 3A). Essentially similar results were obtained inWEHI
231-K13-ERTAM cells grown in the absence of 4OHT. In contrast,
the p65/RelA DNA binding activity was approximately 3-fold
higher in the WEHI 231-K13-ERTAM cells that had been exposed
to 4OHT, suggesting activation of the NF-B pathway by K13
(Fig. 3A). More importantly, treatment with anti-IgM resulted in
only a minor reduction in the nuclear p65/RelA DNA binding
activity in the 4OHT-treated WEHI 231-K13-ERTAM cells
(Fig. 3A). In fact, the 4OHT-treated WEHI 231-K13-ERTAM cells
maintained nearly 2-fold higher p65/RelA DNA binding activity
FIG 2 K13 protects WEHI 231 cells from anti-IgM-induced growth arrest and apoptosis. (A) WEHI 231-K13-ERTAM cells were grown in the presence and
absence of 4OHT (20 nM) and then treated with and without anti-IgM (1 g/ml) for 48 h. Cells were stained with propidium iodide, and cell cycle analysis was
performed using flow cytometry. (B)WEHI 231-K13-ERTAM cells grown in the presence or absence of 4OHT (20 nM) were stained with phycoerythrin-labeled
annexinV after treatment with anti-IgM (1g/ml) for 48 h and examined by flow cytometry. (C)WEHI 231-K13-ERTAM cells grown in the presence and absence
of 4OHTwere treatedwith 1g/ml of anti-IgM. Cells were then stainedwith SytoxGreen, a cell-impermeable nuclear dye that stains the nuclei of dead cells; cells
were then examined under a fluorescence microscope or under phase-contrast microscope and photographed.
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even after anti-IgM treatment than the basal p65/RelADNAbind-
ing activity observed in the cells that had not been treated with
4OHT or anti-IgM (Fig. 3A).
To demonstrate that the increase in p65/RelA DNA binding
activity in the 4OHT-treatedWEHI 231-K13-ERTAM cells is asso-
ciated with a corresponding increase in NF-B transcriptional ac-
tivity, we used lentivirus-mediated gene transfer to generate a
polyclonal population of WEHI 231-K13-ERTAM cells stably ex-
pressing an NF-B-driven luciferase reporter construct. We grew
the WEHI 231-K13-ERTAM-NF-B-Luc cells in the presence and
absence of 4OHT and subsequently treated them with anti-IgM
for 24 h before cell lysis andmeasurement of luciferase activity. As
shown in Fig. 3B, WEHI 231-K13-ERTAM-NF-B-Luc cells
showed low basal NF-B-Luc activity, which was further reduced
by anti-IgM treatment. In contrast, not only did 4OHT treatment
result in a significant increase in the basal NF-B-Luc activity, but
FIG 3 K13 activates the NF-B pathway in WEHI 231 cells. (A) An ELISA-based NF-B binding assay showing increased binding of p65/RelA DNA binding
activity in the nuclear extracts of WEHI 231-vector and WEHI 231-K13-ERTAM cells grown in the presence or absence of 4OHT and treated with 1 g/ml of
anti-IgM for 24 h. Values shown are the mean	 SD from one representative experiment out of three performed in duplicate. Asterisks indicate significance at
aP level of0.05.OD655nm, optical density at 655 nm. (B)A luciferase-based reporter assay showing induction ofNF-B transcriptional activity byK13.WEHI
231 cells stably expressing the K13-ERTAM-NF-B-Luc construct were grown in the presence and absence of 4OHT and treated with 1 g/ml of anti-IgM for 24
h, and cell lysates were used for a luciferase reporter assay. Values shown are the mean 	 SD from one representative experiment out of three performed in
duplicate. Asterisks indicate significance at a P level of0.05. (C)Western blots showing upregulation of A20 and RelB expression in 4OHT-treatedWEHI 231
K13-ERTAM cells and no significant decline following treatment with anti-IgM (1 g/ml). WEHI 231-vector cells treated with 4OHT did not show any increase
in A20 and RelB. Tubulin served as a loading control. (D) Wild-type K13, but not vFLIP E8 or K13-58AAA, induces RelB promoter activity. 293T cells were
transfected with a control vector and a vector encoding wild-type K13 or the K13mutant K13-58AAA or vFLIP E8 (250 ng/ml) along with an RelB-Luc reporter
construct (75 ng/well) and a pRSV/LacZ (-galactosidase) reporter construct (75 ng/well), and the reporter assay was performed as described in Materials and
Methods. The values shown aremean	 SD of one representative experiment out of three in which each transfection was performed in duplicate. (E) Expression
levels of wild-type FLAG-tagged K13, the K13 mutant K13-58AAA, and vFLIP E8 in 293T cells. (F) K13 activates RelB promoter through NF-B the pathway.
293T cells were transfected with a control vector or a vector encoding K13 along with either a WT-RelB-Luc or RelB-Luc construct containing mutations in
NF-B RE I (Mut I), NF-B RE II (Mut II), or both (Mut 1II). The experiment was performed as described in for panel D. (G) Dominant negative mutants of
IB lacking the N-terminal 36 amino acids (IBN) and a superrepressor form of IB (IB SS32/36AA) block K13-induced RelB promoter activity. 293T
cells were transfected either with an empty vector or K13, along with an RelB luciferase reporter construct and a pRSV/LacZ reporter construct, as described for
panel F. The amount of inhibitor plasmids (500 ng/well) was 5 times the amount of vector orK13 (100 ng/well) plasmid, and the total amount of transfectedDNA
was kept constant by adding an empty vector. The values shown are themean	 SD of one representative experiment out of three in which each transfection was
performed in duplicate. (H) As2O3, an inhibitor of NF-B, blocks K13-induced RelB promoter activation. 293T cells were transfected with an empty vector or
a vector encoding K13 along with RelB-Luc and pRSV/LacZ reporter constructs. Approximately 3 h after transfection, cells were treated with control vehicle or
2.5 MAs2O3 for 18 h before cell lysis and measurement of reporter activities.
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also this activity remained significantly higher than the activity
observed in the uninduced cells even after treatment with anti-
IgM (Fig. 3B). Thus, K13 is able to sustainNF-B signaling even in
the presence of anti-IgM.
To examine if an increase in NF-B signaling by K13 translates
into an increase in the expression of downstream targets of the
NF-B pathway, we examined the status of A20 and RelB, two
proteins that are known to be upregulated by NF-B activation.
Western blot analyses revealed low basal expression of A20 and
RelB in uninduced WEHI 231-K13-ERTAM cells that was further
reduced by IgM treatment. In contrast, the basal levels of bothA20
and RelB were significantly higher in 4OHT-treated WEHI 231-
K13-ERTAM cells and remained so following IgM treatment. As a
control, we also examined the levels of A20 and RelB in WEHI
231-vector cells and observed no significant differencewith 4OHT
treatment (Fig. 3C).
K13 upregulates RelB expression in WEHI 231 cells through
NF-B activation. RelB is not only amember of theNF-B family
but also an NF-B target gene (30). Previous studies have shown
that CD40 signaling protects WEHI 231 cells against anti-IgM-
induced apoptosis by upregulating RelB expression (31). To de-
termine the role of RelB in K13-induced protection against anti-
IgM-induced apoptosis, we examined the level of RelB expression
inWEHI 231-K13-ERTAM cells. As shown in Fig. 3C, expression of
RelB was significantly increased in WEHI 231-K13-ERTAM cells
upon treatment with 4OHT, and this elevated level was sustained
even following treatment with anti-IgM. In contrast, 4OHT had
no effect on RelB level in WEHI 231-vector cells (Fig. 3C). To
determine themechanism by which K13 upregulates RelB expres-
sion, we cotransfected a relB promoter-driven luciferase reporter
construct with an empty vector or a K13 expression plasmid. K13
strongly induced relB promoter activity compared to vector-
transfected cells (Fig. 3D). In contrast, no induction of relB pro-
moter activity was observed upon expression of an NF-B-defec-
tivemutant of K13 with three alanine substitutions at positions 58
to 60 (K13-58AAA) (Fig. 3D). The equine herpesvirus 2-encoded
vFLIP E8 resembles K13 in structure but lacks the ability to acti-
vate theNF-Bpathway (11). As shown in Fig. 3D andE, vFLIP E8
failed to activate the relB promoter. Collectively, the above results
support the argument that K13 activates the relB promoter via
NF-B activation.
The human relB promoter contains two NF-B response ele-
ments located at positions247 to238 and175 to166 from
the translation start site anddesignatedNF-BRE I andNF-BRE
II, respectively (23). To delineate the contribution of theseB sites
in K13-induced relB promoter activation, we tested the ability of
K13 to activate luciferase reporter constructs driven by either the
wild-type relB promoter or relB promoters containing mutations
in one or both of the B response elements. As shown in Fig. 3F,
while K13 strongly activated the wild-type relB promoter and the
promoter containing a mutation in the NF-B RE I, it failed to
activate relB promoters containing mutations in NF-B RE II or
both NF-B RE I and II. Thus, K13 upregulates relB transcription
through the NF-B RE II. Finally, to confirm the role of the clas-
sical NF-B pathway in K13-induced relB promoter activity, we
used genetic and pharmacological inhibitors of this pathway. K13-
induced relB promoter activity was blocked by a superrepressor
form of IB in which the two critical serine residues have been
mutated to alanine (IB SS32/36AA) and a deletion mutant of
IB lacking the N-terminal 36 amino acids (IBN) (Fig. 3G).
Finally, As2O3, an agent known to block the K13-induced classical
NF-B pathway, effectively blocked relB promoter activity in-
duced by K13 expression (Fig. 3H). Taken collectively, the above
results confirm that K13 upregulates RelB expression through
classical NF-B activation.
Protective effect of K13 against anti-IgM-induced growth ar-
rest and apoptosis is specific to its ability to activate the NF-B
pathway and upregulate RelB. The studies in the preceding sec-
tions demonstrated that the protective effect of K13 against anti-
IgM-induced growth arrest and apoptosis is associated with the
activation of the NF-B pathway. To determine if NF-B activa-
tion is functionally involved in the above processes, we generated
stable polyclonal populations of WEHI 231 cells expressing the
K13-58AAAmutant and vFLIP E8, which lack NF-B activity (11,
20). The expression of K13-58AAA and the vFLIP E8 inWEHI 231
cells was confirmed by immunoblotting (Fig. 4A). Consistentwith
their inability to activate theNF-B pathway, K13-58AAA and the
vFLIP E8 failed to induce the expression of A20 and RelB, while
robust activation of these proteins was seen in the wild-type K13-
expressing cells (Fig. 4B). We next compared the ability of wild-
type K13, K13-58AAA, and vFLIP E8 to protect against IgM-in-
duced apoptosis. In contrast to K13, both E8 and K13-58AAA
conferred no protective effect against anti-IgM-induced apoptosis
in WEHI 231 cells (Fig. 4C). Finally, to confirm the functional
involvement of RelB in the protective effect conferred by K13
expression, we studied the effect of its downregulation on anti-
IgM-induced cell death. Downregulation of RelB in the WEHI
231-K13 cells by siRNA resulted in a significant reduction in cell
viability following anti-IgM treatment compared to the control
siRNA-transfected cells (Fig. 4D and E). Essentially similar results
were obtained upon silencing of RelB in K13-ERTAM cells
(Fig. 4F). Thus, the protective effect of K13 against anti-IgM-in-
duced growth arrest and apoptosis is conferred through upregu-
lation of RelB via increased classical NF-B activity.
Protective effect of K13 against anti-IgM-induced growth ar-
rest in WEHI 231 cells is associated with modulation of c-Myc
and p27Kip1 expression. The murine oncogene c-myc has been
extensively studied with respect to its role in growth arrest and
induction of apoptosis in WEHI 231 cells upon engagement of
IgM (32–34). Cross-linking of IgM results in a transient increase
followed by a rapid decrease in c-myc transcript levels (32, 33).
The c-myc gene containsBbinding sites, and theNF-Bpathway
is known to modulate c-myc activity (35). To ascertain if the pro-
tective effect of K13 against anti-IgM-induced growth arrest and
cell death is due in part to maintenance of c-myc level, we utilized
quantitative real-timePCRanalysis to determine changes in c-myc
transcript levels upon anti-IgM treatment.While anti-IgM led to a
significant reduction in c-myc mRNA levels in the untreated
WEHI 231-K13-ERTAM cells, it had no significant effect on c-myc
mRNA in cells that had been pretreated with 4OHT to induce K13
activity (Fig. 5A). Furthermore, the basal level of c-Myc protein
was significantly higher in the WEHI 231-K13 cells than in cells
expressing an empty vector, K13-58AAA, or vFLIP E8, supporting
the involvement of K13-induced NF-B activity in the upregula-
tion of c-Myc (Fig. 5B). More importantly, while anti-IgM treat-
ment resulted in a 2-fold reduction in the level of c-Myc protein in
the WEHI 231-vector cells, it had only a marginal effect on the
c-Myc protein level in the WEHI 231-K13 cells (Fig. 5C). In fact,
the level of c-Myc protein in WEHI 231-K13 cells even following
anti-IgM treatment was higher than its basal level in the untreated
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WEHI 231-vector cells (Fig. 5C). To determine the functional
involvement of c-Myc in the protective effect conferred by K13,
we used siRNA-mediated gene silencing to downregulate its
expression (Fig. 5D). siRNA-mediated silencing of c-Myc expres-
sion in WEHI 231-K13 cells resulted in reduced cell viability fol-
lowing anti-IgM treatment compared to the control siRNA-trans-
fected cells (Fig. 5E). Essentially similar results were obtained
upon c-Myc silencing in WEHI 231-K13-ER cells (Fig. 5F). We
also used a pharmacological approach to downregulate c-Myc ex-
pression. JQ1 is a recently described small-molecule inhibitor of
BET bromodomains that downregulate c-mycmRNA and expres-
sion of its downstream target genes (36). Treatment of WEHI
231-K13 cells with 50 nM and 100 nM JQ1 resulted in a dose-
dependent suppression of c-Myc expression, which was accompa-
nied by reduction in cell viability following IgM treatment (Fig.
5G andH). Taken collectively, the above results support the argu-
ment that K13 protects WEHI 231 cells against anti-IgM-induced
cell death via upregulation of c-Myc.
The cyclin-dependent kinase inhibitor p27Kip1 has been shown
to promote cell cycle arrest and apoptosis inWEHI 231 cells upon
engagement of the BCR (33, 34). p27Kip1 is repressed by c-Myc,
and a reduction in c-Myc expression has been shown to be suffi-
cient to induce p27Kip1 expression (33, 34). As shown in Fig. 5I,
treatment with anti-IgM resulted in upregulation of p27Kip1 levels
in WEHI 231-vector cells, which was blocked in WEHI 231-K13
cells. Collectively, the above results suggest that K13 protects
against anti-IgM-induced growth arrest by blocking the fall in
c-Myc level and resulting upregulation of p27Kip1.
Protective effect of K13 against anti-IgM-induced apoptosis
in WEHI 231 cells is associated with modulation of Mcl-1 ex-
pression. We have previously shown that K13 protects against
growth factor withdrawal-induced apoptosis by upregulating the
expression of Mcl-1, an antiapoptotic member of the Bcl2 family
(18, 24). To determine if upregulation of Mcl-1 is also involved in
the protective effect of K13 against BCR-induced apoptosis, we
examined its status by Western blotting. As shown in Fig. 6A, the
expression of Mcl-1 was increased inWEHI 231-K13-ERTAM cells
upon 4OHT treatment, and this elevated expression was main-
tained following treatmentwith anti-IgM.To investigate the func-
tional role of Mcl-1 upregulation in the K13-mediated protection
against anti-IgM-induced apoptosis, we generated a stable popu-
lation of WEHI 231 cells with ectopic Mcl-1 expression by retro-
virus-mediated gene transfer (Fig. 6B).WEHI 231 cells expressing
Mcl-1 or an empty vector were treated with anti-IgM for 48 h. As
shown in Fig. 6C, WEHI 231-Mcl-1 cells were significantly pro-
tected from anti-IgM-induced cell death compared to the WEHI
231-vector cells. To determine the functional role of Mcl-1 in the
protection conferred by K13, we used siRNA-mediated gene si-
lencing to downregulate its expression (Fig. 6D). WEHI 231-K13
cells transfected with Mcl-1 siRNA showed reduced cell viability
following anti-IgM treatment compared to the control siRNA-
transfected cells (Fig. 6E). Essentially similar results were obtained
uponMcl-1 silencing in theWEHI 231-K13-ERTAM cells (Fig. 6F).
Taken collectively, the above results suggest that K13 protects
against anti-IgM-induced apoptosis by upregulating Mcl-1 ex-
pression.
FIG 4 The protective effect of K13 against anti-IgM-induced apoptosis is dependent on NF-B signaling. (A) Expression of K13, K13-58AAA, and vFLIP E8 in
WEHI 231 cells as determined by immunoprecipitation with FLAG beads followed by immunoblot analysis with a FLAG antibody. The asterisk denotes a
nonspecific band. (B) Western blot analysis showing expression of A20 and RelB in WEHI 231 cells expressing wild-type K13, K13-58AAA, and vFLIP E8.
GAPDH served as a loading control. The blot was imaged using anOdyssey Infrared Imaging System. (C)WEHI 231 cells expressing wild-type K13, K13-58AAA,
and the vFLIP E8 were subjected to anti-IgM treatment at the indicated concentrations. Cell viability wasmeasured using anMTS assay (values are means	 SD;
n 
 3). (D) Western blot analysis showing siRNA-mediated knockdown of RelB expression in WEHI 231-K13 cells. The blot was reprobed with an antibody
against GAPDH (bottompanel) to show equal loading and specificity of gene silencing. The blot was imaged using anOdyssey Infrared Imaging System.G3PDH,
glyceraldehyde-3-phosphate dehydrogenase. (E and F) Downregulation of RelB in the WEHI 231-K13 and WEHI 231-K13-ERTAM cells by siRNA results in a
significant reduction in cell viability following anti-IgM (1 g/ml) treatment compared to the control siRNA-transfected cells. The experiment was performed
as described in the legend of Fig. 3C. Values shown are themeans	 SD from one representative experiment out of two performed in triplicate. Asterisks indicate
statistical significance at a P level of0.05.
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K13 is able to protect the mature human B-cell line Ramos
from anti-IgM induced apoptosis. To ascertain if the protective
effect of K13 is not developmentally restricted, we used themature
human B-cell line Ramos. Polyclonal populations of Ramos cells
expressing K13 (Ramos-K13) or an empty vector (Ramos-vector)
were generated using retroviral gene transfer, and the expression
of K13 was confirmed by immunoblotting (Fig. 7A). The level of
retrovirally expressedK13 in the Ramos-K13 cells was comparable
to the physiological level of K13 found in the PEL cell line BC1
(Fig. 7A). Next, the ability of K13 to protect against anti-IgM-
induced growth inhibition was examined by growing Ramos-K13
and Ramos-vector cells with anti-IgM. Expression of K13 con-
ferred a protective effect against anti-IgM-induced growth arrest
as measured by the MTS-based assay (Fig. 7B). Anti-IgM treat-
ment of Ramos-vector cells resulted in a decline in cells in S andG2
phases from 41% to 32% and from 18% to 10%, respectively.
However, this decline in cells in the S and G2 phases was not
mirrored by a corresponding increase in cells in the G0/G1 phase
due to an increase in apoptosis, as reflected by an increase in cells
in the sub-G0/G1 fraction from 7% to 25% (Fig. 7C). All of the
above responses to anti-IgM were attenuated in K13-expressing
Ramos cells. As shown in Fig. 7C, anti-IgM treatment of Ramos-
K13 cells resulted in a smaller decline in cells in the S (from40% to
37%) and G2 (from 22% to 17%) phases and a corresponding
smaller increase in cells in the sub-G0/G1 fraction (from 7% to
11%). Thus, in contrast to WEHI 231 cells, Ramos cells primarily
undergo apoptosis in response to anti-IgM treatment, and this
response is blocked upon K13 expression.
To determine the mechanism by which K13 protects Ramos
cells against IgM-induced arrest and apoptosis, we examined the
status of NF-B and its downstream target genes. Treatment of
Ramos-vector cells with anti-IgM resulted in downregulation of
NF-B as measured by a nuclear p65/RelA DNA binding assay
(Fig. 7D). Consistent with the ability of K13 to activate the NF-B
pathway, the basal level of nuclear p65/RelA was significantly
higher in Ramos-K13 cells than in Ramos-vector cells (Fig. 7D).
Although anti-IgM treatment resulted in a decline in the nuclear
p65/RelA in the Ramos-K13 cells as well, its level was significantly
FIG 5 K13 exerts its protective effect against anti-IgM-induced apoptosis through modulation of c-Myc and p27Kip1 levels. (A) Real-time RT-PCR analysis
showing decline in c-myc levels inWEHI 231-K13 cells following treatmentwith anti-IgM for 24 h thatwas blocked by induction ofK13 activity by treatmentwith
4OHT. Results shown are the means 	 SD (n 
 2). (B) Western blot analysis showing expression of c-Myc in the WEHI 231 cells expressing wild-type K13,
K13-58AAA, and vFLIP E8.G3PDHserved as a loading control. Blots were imaged using anOdyssey Infrared Imaging system. (C) Immunoblot analysis ofWEHI
231-K13 cells grown in the presence and absence of 4OHT (20 nM)when treatedwith anti-IgM (1g/ml) for 24 h. K13 blocks anti-IgM-induced downregulation
of c-Myc. Tubulin served as a loading control. (D) Immunoblot analysis with Odyssey Infrared Imaging System showing siRNA-mediated knockdown of c-Myc
expression inWEHI 231-K13 cells. (E and F) Silencing of c-Myc in theWEHI 231-K13 andWEHI 231-K13-ERTAM cells results in a significant reduction in cell
viability following anti-IgM treatment compared to the control siRNA-transfected cells. Values shown are the means	 SD from one representative experiment
out of two performed in triplicate. (G)Western blot analysis showing suppression of c-Myc expression by a 24-h treatment with the indicated doses of JQ1. The
G3PDH blot shows equal loading. (H) WEHI 231-K13 cells treated with JQ1 show a reduction in cell viability following anti-IgM (1 g/ml) treatment. (I)
Immunoblot analysis of WEHI 231-K13 cells grown in the presence and absence of 4OHT (20 nM) when treated with anti-IgM (1 g/ml) for 24 h. K13 blocks
anti-IgM-induced upregulation of p27Kip1. Tubulin served as a loading control.
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higher than in the anti-IgM-treated Ramos-vector cells (Fig. 7D).
We next compared the status of several downstream targets of the
NF-B pathway in the Ramos-vector and -K13 cells by Western
blotting. The activation of the NF-B pathway in the Ramos-K13
cells was associated with a significant increase in the expression of
RelB, and its elevated level was maintained following anti-IgM
treatment (Fig. 7E). Additionally, while anti-IgM treatment of
Ramos-vector cells resulted in a 2-fold reduction in the expression
FIG 6 K13 exerts its protective effect against anti-IgM-induced apoptosis through upregulation of Mcl-1. (A) Immunoblot showing expression of Mcl-1 in
K13-ERTAM cells that had been left untreated or treated with 4OHT and then exposed to anti-IgM (1g/ml) over a 48-h time period. Tubulin served as a loading
control. (B) Immunoblot analysis showing ectopic expression of Mcl-1 in WEHI 231 cells. Tubulin served as a loading control. (C) WEHI 231 cells expressing
an empty vector orMcl-1 were grown in triplicate in a 96-well plate in the presence or absence of anti-IgM (1g/ml). Cell viability wasmeasured 48 h later using
anMTS assay (values are means	 SD; n
 3). (D)Western blot analysis showing siRNA-mediated knockdown of Mcl-1 expression inWEHI 231-K13 cells. (E
and F) Downregulation of Mcl-1 in the WEHI 231-K13 and WEHI 231-K13-ERTAM cells by siRNA results in a significant reduction in cell viability following
anti-IgM treatment compared to the control siRNA-transfected cells. Values shown are the means 	 SD from one representative experiment out of two
performed in triplicate. Asterisks indicate statistical significance at a P level of0.05.
FIG 7 K13 protects against anti-IgM-induced apoptosis in themature B-cell line Ramos through activation of theNF-B pathway. (A) Expression of retrovirally
expressed K13-FLAG in Ramos cells and endogenous K13 in BC1 cells as determined by immunoblotting with 8F6 monoclonal antibody. Tubulin serves as a
loading control. (B) Ramos cells expressing an empty vector or K13 were grown in triplicate in a 96-well plate with anti-IgM (30 g/ml). Cell viability was
measured using the MTS assay (values are means	 SD; n
 3). Asterisks indicate significance at a P level of0.05. (C) Ramos cells expressing an empty vector
or K13 were treated with or without anti-IgM (30 g/ml) for 24 h. Cells were stained with propidium iodide, and cell cycle analysis was performed using flow
cytometry. Values shown are the percentage of cells in the different phases of the cell cycle. (D) An ELISA-based NF-B binding assay showing p65/RelA DNA
binding activity in the nuclear extracts of Ramos cells expressing an empty vector or K13 treated with or without 30g/ml of anti-IgM for 24 h. The values shown
are means	 SD of one representative experiment out of three in which p65 DNA binding was measured in duplicate. Asterisks indicate significance at a P level
of0.05. (E) Immunoblotting showing expression of RelB, Mcl-1, and Bcl2 in Ramos cells expressing an empty vector or K13 when treated with anti-IgM (30
g/ml) over a 48-h time period.
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of Mcl-1 protein by 48 h, the expression of Mcl-1 was maintained
in the Ramos-K13 cells. Finally, Bcl-2 expression was detected
only in the Ramos-K13 cells, and its level was maintained during
anti-IgM exposure (Fig. 7E). Taken collectively, these results pro-
vide further evidence that K13 is able to protect B cells from anti-
IgM-induced apoptosis through activation of theNF-Bpathway.
DISCUSSION
The signaling mechanisms involved in BCR-induced apoptosis
are complex and have been extensively studied in bothmature and
immature B cells (2, 37). These studies have revealed that BCR-
mediated apoptosis is primarily mediated via the intrinsic apop-
tosis pathway and is associated with enhanced permeability of the
mitochondrial outer membrane and the activation of caspase-9
and -3 (38). On the other hand, BCR-mediated apoptosis is be-
lieved to be independent of FADD (Fas-associated death domain)
and caspase-8, which are components of the extrinsic apoptosis
pathway (38). In addition to the intrinsic apoptosis pathway, the
NF-B pathway has also been shown to play a key role in BCR-
induced apoptosis, and it has been shown that BCR-induced
apoptosis in WEHI 231 cells is preceded by a drop in the basal
NF-B activity (28, 29, 31).
K13 was originally believed to act as an inhibitor of caspase-8/
FLICE that protected virally infected cells against death receptor-
induced apoptosis (10). However, subsequent studies revealed
that K13 is not an inhibitor of caspase-8/FLICE but, instead, is a
strong activator of the NF-B pathway (11, 12, 15, 20). In this
study, we demonstrate that K13 protects against BCR-induced
apoptosis via NF-B activation, independent of its activity as a
caspase-8 inhibitor. This conclusion is supported by our results
showing that the protective effect of K13 against BCR-induced
apoptosis was associated with not only an increase in basal NF-B
activity in these cells but also maintenance of this activity follow-
ing treatment with anti-IgM. It has previously been reported that
BCR-induced apoptosis in WEHI 231 cells can be reversed by
treatment with CD40 ligand (CD40L) (28). Interestingly, similar
to K13, CD40L rescue was shown to prevent the drop in NF-B/
Rel binding induced by anti-IgM treatment (31). Thus, K13mim-
ics CD40 signaling to protect against BCR-induced apoptosis. The
involvement of the NF-B pathway in the K13 rescue is further
supported by our results with the NF-B defective mutant of K13,
K13-58AAA, which failed to confer protection against BCR-in-
duced apoptosis. Finally, the vFLIP E8, which has been shown to
protect against Fas-induced apoptosis by blocking caspase-8/
FLICE but lacks the ability to activate NF-B, failed to protect
against BCR-induced apoptosis. Taken collectively, the above re-
sults demonstrate that K13 protects against BCR-induced apop-
tosis through NF-B activation and not via inhibition of
caspase-8. These results are also consistent with the previous stud-
ies demonstrating a lack of involvement of FADDand caspase-8 in
BCR-induced apoptosis (1, 2).
The CD40L rescue of WEHI 231 cells against BCR-induced
apoptosis was also associated with increased expression of the
NF-B subunit RelB (31). More importantly, siRNA-mediated
knockdown of RelB inWEHI 231 cells was shown to substantially
increase their susceptibility to anti-IgM-induced apoptosis while
ectopic expression of RelB was shown to confer protection (31).
Based on these reports, we examined the status of RelB and ob-
served significant upregulation of RelB expression in the K13-
expressing WEHI 231 and Ramos cells. The relB promoter con-
tains twoBbinding sites, and previous studies have reported that
the NF-B RE II is involved in transcriptional activation of relB
promoter by agents known to activate the classical NF-B path-
way, such as tumor necrosis factor (TNF) and lipopolysaccharide
(LPS) (30). Consistent with these studies, we observed that K13
strongly activated a luciferase reporter construct driven by the
wild-type relB promoter but failed to activate a construct contain-
ing a mutation in the NF-B RE II. Furthermore, K13-induced
relB promoter activation was effectively blocked by genetic and
pharmacological inhibitors of the classical NF-B pathway. Taken
collectively, these results demonstrate that K13 upregulates relB
gene expression via activation of the classical NF-B pathway.
Although RelB expression was strongly upregulated in K13-ex-
pressingWEHI 231 and Ramos cells, it is important to clarify that
we are not contending that RelB is the soleNF-B subunit respon-
sible for the protective effect of K13 against BCR-induced apop-
tosis. Instead, we favor the hypothesis that RelB works in concert
with other NF-B subunits to regulate the expression of genes
responsible for protection against BCR-induced apoptosis.
BCR engagement inWEHI 231 cells, following anti-IgM treat-
ment, is accompanied by a fall in c-Myc and a rise in p27Kip1
protein levels (32, 33). The changes in c-Myc and p27Kip1 levels
have been shown to be functionally involved in anti-IgM-induced
growth arrest and apoptosis in WEHI 231 cells (32, 33). Consis-
tent with these prior studies, we also observed that a decline in
NF-B following anti-IgM treatment inWEHI 231 cells is accom-
panied by a decline in c-Myc and an increase in p27Kip1 protein
levels. However, not only was the basal level of c-Myc significantly
higher in the K13-expressing WEHI 231 cells than in the vector
cells, but it also remained at elevated levels even following anti-
IgM treatment. Similarly, the anti-IgM-induced rise in p27Kip1
was blocked in K13-expressing cells. Finally, the NF-B-respon-
sive genes that are known to protect against BCR-induced apop-
tosis also include members of the Bcl-2 family. Consistent with
these studies, we observed significant upregulation of Mcl-1 ex-
pression in K13-expressing WEHI 231 and Ramos cells. Further-
more, ectopic expression of Mcl-1 in WEHI 231 cells resulted in
protection against IgM-induced apoptosis. Taken collectively
with previous studies, our results support the hypothesis that K13
protects against anti-IgM-induced growth arrest and apoptosis by
preventing the fall in c-Myc levels, thereby blocking the rise in
p27Kip1, and by upregulating Mcl-1.
The gammaherpesviruses that include KSHV, Epstein-Barr vi-
rus (EBV) and the murine gammaherpesvirus 68 (MHV-68), are
able to establish life-long persistent infections in lymphocytes.
Themanipulation of BCR signaling events in order to successfully
establish a latent infection in B lymphocytes is a common strategy
among gammaherpesviruses. For example, EBV through the pro-
teins LMP-1, which mimics CD40 signaling, and LMP-2A, which
acts as a constitutively activated B-cell receptor, are able to dereg-
ulate BCR signaling and enhance cell survival and proliferation
(39, 40). Similarly, the MHV-68 protein M2 has been shown to
block BCR-induced arrest and apoptosis through upregulation of
Vav activity (41). Here, we show that expression of K13 protects
against BCR-mediated cell cycle arrest and apoptosis through
NF-B activation, providing yet another example of how gamma-
herpesviruses manipulate this signaling pathway to promote the
survival and proliferation of virally infected cells.
Our results have significance for the pathogenesis of KSHV-
associated lymphoproliferative disorders. The KSHV-positive
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plasmablasts in MCD express IgM (7–9), and K13-transgenic
mice have been shown to develop an MCD-like disease (42). It is
conceivable that inhibition of anti-IgM-induced apoptosis com-
bined with the known ability of K13 to promote cellular prolifer-
ation (20) may contribute to the accumulation of IgM-expressing
plasmablasts and autoimmune manifestations seen in MCD (43–
45). Finally, our results may also have implications for the patho-
genesis of KSHV-associated PEL. Although the PEL cells generally
lack surface IgM expression, KSHV was recently shown to selec-
tively establish infection in IgM()-expressing B cells (46). This
has led to the suggestion that PEL and MCD may share an IgM-
expressing progenitor and that the lack of surface IgM expression
in PEL cells is due to postinfection events that drive their differ-
entiation into late-plasmablast stage, a stage known to be associ-
ated with loss of surface IgM (46). Therefore, K13 may also con-
tribute to the pathogenesis of PEL by blocking anti-IgM-induced
apoptosis of IgM()-expressing PEL progenitor cells, which after
accumulation of additional genetic and epigenetic alterations
leads to the development of PEL. This hypothesis is consistent
with the development of lymphoma with an immuno-phenotype
resembling PEL in K13-transgenic mice (42, 47).
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